S 326 118th Congress Senate Armed Forces and National Security Alternative treatments Congressional oversight Drug trafficking and controlled substances Government studies and investigations Health information and medical records Medical research Mental health Neurological disorders Veterans' medical care

VA Medicinal Cannabis Research Act of 2023

Introduced: February 9, 2023 See on congress.gov

Everywhere this bill has been 9 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Apr 26, 2023

Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate.

Apr 26, 2023

Cloture on the motion to proceed to the measure not invoked in Senate by Yea-Nay Vote. 57 - 42. Record Vote Number: 97.

Apr 20, 2023

Cloture motion on the motion to proceed to the measure presented in Senate. (CR S1286)

Apr 20, 2023

Motion to proceed to consideration of measure made in Senate.

Mar 23, 2023

Placed on Senate Legislative Calendar under General Orders. Calendar No. 32.

Mar 23, 2023

Committee on Veterans' Affairs. Reported by Senator Tester without amendment. Without written report.

Feb 16, 2023

Committee on Veterans' Affairs. Ordered to be reported without amendment favorably.

Feb 9, 2023

Read twice and referred to the Committee on Veterans' Affairs.

Feb 9, 2023

Introduced in Senate

Plain-English summary Congressional Research Service

VA Medicinal Cannabis Research Act of 2023

This bill requires the Department of Veterans Affairs (VA) to study the effects of cannabis on veterans who are enrolled in the VA health care system and have been diagnosed with post-traumatic stress disorder (PTSD) or chronic pain (i.e., eligible veterans).

First, the bill requires the VA to conduct an observational, 18-month study on the effects of cannabis on the health outcomes of eligible veterans. The VA must report on the study and address whether it is able to meet criteria necessary to conduct clinical trials.

Then, if the VA determines that it is able to proceed, it must carry out a series of clinical trials on the effects of cannabis appropriate for investigational use, as determined by the Food and Drug Administration, on the outcomes of eligible veterans. The VA must carry out a long-term observational study of the clinical trial participants.

The VA may terminate the trials if it is unable to meet clinical guideline requirements or the trials would create excessive risk to participants.

The VA must ensure that the study and trials are representative of the demographics of veterans in the United States, as determined by the most recent data from the American Community Survey of the Bureau of the Census.

The study and trials must include mechanisms to ensure data preservation and registration as necessary (in an anonymous form).

What's happening now April 26, 2023

Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate.

Committees of jurisdiction 1